Black Diamond Therapeutics, Inc. (BDTX)
NASDAQ: BDTX · Real-Time Price · USD
2.275
-0.035 (-1.52%)
May 28, 2026, 2:43 PM EDT - Market open
BDTX Revenue
In the year 2025, Black Diamond Therapeutics had annual revenue of $70.00M.
Revenue (ttm)
$70.00M
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
21
Market Cap
130.36M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 70.00M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Agenus | 123.87M |
| Alpha Cognition | 10.83M |
| Alps Group | 3.74M |
| Kazia Therapeutics | 1.27M |
| Spruce Biosciences | 697.00K |
| Cardiff Oncology | 525.00K |
| Connect Biopharma Holdings | 233.00K |
| NeOnc Technologies Holdings | 39.99K |
BDTX News
- 6 days ago - Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference - GlobeNewsWire
- 6 days ago - Black Diamond Therapeutics Lung Cancer Drug Shows 15.2-Month PFS in Phase 2 Study - MarketBeat
- 6 days ago - Black Diamond Therapeutics Transcript: Study result - Transcripts
- 6 days ago - Black Diamond Therapeutics Press release: Study result - Filings
- 6 days ago - Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations - GlobeNewsWire
- 7 days ago - Black Diamond Therapeutics Slides: Corporate presentation - Filings
- 9 days ago - Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC - GlobeNewsWire
- 21 days ago - Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire